| Dual-mode interaction between quercetin and DNA-damaging drugs in cancer cells. | |
| | |
MedLine Citation:
|
PMID: 22213289 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: DNA-damaging drugs constitute standard chemotherapy regimen for advanced colorectal cancer. Here, the interactions between quercetin and 5-fluorouracil (5-FU), etoposide, and camptothecin were examined in cancer cells. MATERIALS AND METHODS: HCT116 colorectal or PPC1 prostate cancer cells were treated with quercetin and the drugs. Clonogenicity assays, cell cycle profiles, and expressions of p53, p21, BAX, survivin and cyclin B1 proteins were used to examine the effects of the treatments. RESULTS: Quercetin synergistically inhibited the clonogenicity of the wild-type cells, but inhibited the cell cycle effects of all the drugs tested. In p53-null cells, the combination of low dose 5-FU with up to 6 μM quercetin promoted clonogenic survival. Treatment of p53-wild-type cells with 50 μM quercetin reduced drug-induced up-regulation of p53, p21 and BAX. The combination of quercetin and the drugs also reduced the levels of cyclin B1 and survivin proteins. CONCLUSION: While high doses of quercetin synergize with DNA-damaging agents, the effect of drug combination with quercetin is influenced by the effective doses and the p53 status of the cells. |
| | |
Authors:
|
Temesgen Samuel; Khalda Fadlalla; Lachundra Mosley; Venkat Katkoori; Timothy Turner; Upender Manne |
Related Documents
:
|
22023319 - Humanized transgenic mouse models for drug metabolism and pharmacokinetic research. 1801159 - Fine structure of microfilariae in the skin of onchocerciasis patients after exposure t... 20235789 - Human lymphoblastoid cell line panels: novel tools for assessing shared drug pathways. 22053709 - Hydrogels as intracellular depots for drug delivery. 358919 - Inhibition of cell division of escherichia coli by a new synthetic penicillin, piperaci... 6130849 - Taxol induces microtubule assembly at low temperature. 23541379 - Pharmacokinetic studies of protein drugs: past, present and future. 20021229 - Liquid crystalline pluronic 105 pharmacogels as drug delivery systems: preparation, cha... 17681499 - On the chemical synthesis and drug delivery response of folate receptor-activated, poly... |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Anticancer research Volume: 32 ISSN: 1791-7530 ISO Abbreviation: Anticancer Res. Publication Date: 2012 Jan |
Date Detail:
|
Created Date: 2012-01-03 Completed Date: 2012-02-24 Revised Date: 2013-05-08 |
Medline Journal Info:
|
Nlm Unique ID: 8102988 Medline TA: Anticancer Res Country: Greece |
Other Details:
|
Languages: eng Pagination: 61-71 Citation Subset: IM |
Affiliation:
|
Department of Pathobiology, College of Veterinary Medicine, Nursing and Allied Health, Tuskegee University, Tuskegee, AL 36088, USA. tsamuel@mytu.tuskegee.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antineoplastic Combined Chemotherapy Protocols
/
pharmacology* Antioxidants / pharmacology* Apoptosis / drug effects Blotting, Western Camptothecin / administration & dosage Cell Cycle / drug effects Cell Line, Tumor Cell Proliferation / drug effects Colorectal Neoplasms / drug therapy*, metabolism, pathology Cyclin B1 / metabolism Cyclin-Dependent Kinase Inhibitor p21 / metabolism DNA Damage / drug effects* Drug Synergism Etoposide / administration & dosage Flow Cytometry Fluorouracil / administration & dosage Humans Inhibitor of Apoptosis Proteins / metabolism Male Prostatic Neoplasms / drug therapy*, metabolism, pathology Quercetin / pharmacology* Tumor Stem Cell Assay Tumor Suppressor Protein p53 / metabolism bcl-2-Associated X Protein / metabolism |
| Grant Support | |
ID/Acronym/Agency:
|
2 U54 CA118948-06/CA/NCI NIH HHS; G12 MD007585/MD/NIMHD NIH HHS; G12 RR003059/RR/NCRR NIH HHS; G12RR003059/RR/NCRR NIH HHS; SC2 CA138178/CA/NCI NIH HHS; SC2CA138178/CA/NCI NIH HHS; U54 CA118638/CA/NCI NIH HHS; U54 CA118948/CA/NCI NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Antioxidants; 0/BAX protein, human; 0/BIRC5 protein, human; 0/CCNB1 protein, human; 0/CDKN1A protein, human; 0/Cyclin B1; 0/Cyclin-Dependent Kinase Inhibitor p21; 0/Inhibitor of Apoptosis Proteins; 0/TP53 protein, human; 0/Tumor Suppressor Protein p53; 0/bcl-2-Associated X Protein; 117-39-5/Quercetin; 33419-42-0/Etoposide; 51-21-8/Fluorouracil; 7689-03-4/Camptothecin |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Combinations of resveratrol, cisplatin and oxaliplatin applied to human ovarian cancer cells.
Next Document: Mutated in Colorectal Cancer Protein Modulates the NF?B Pathway.